Monique L. Den Boer

Monique L. Den Boer

Auto-generated profile, based on publicly available information

Monique L. Den Boer

Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2001 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
SAScott A. Armstrong
Scott A. Armstrong
JSJane E. Staunton
Jane E. Staunton
LSLewis B. Silverman
Lewis B. Silverman
RPRob Pieters
Rob Pieters
MBMonique L. Den Boer
Monique L. Den Boer
SKStanley J. Korsmeyer
Stanley J. Korsmeyer

1 February 2009 in The Lancet Oncology
Verified
Journal Article
Closed access
MBMonique L Den Boer
Monique L Den Boer
MSMarjon van Slegtenhorst
Marjon van Slegtenhorst
RMRenée X De Menezes
Renée X De Menezes
MCmeyling cheok
meyling cheok
JBJessica Gcam Buijs-Gladdines
Jessica Gcam Buijs-Gladdines
RPRob Pieters
Rob Pieters

5 August 2004 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
AHAmy Holleman
Amy Holleman
MCmeyling cheok
meyling cheok
MBMonique L. Den Boer
Monique L. Den Boer
WYWenjian Yang
Wenjian Yang
AVAnjo J.P. Veerman
Anjo J.P. Veerman
WEWilliam E. Evans
William E. Evans
Childhood acute lymphoblastic leukemia (ALL) is curable with chemotherapy in approximately 80 percent of patients. However, the cause of treatment failure in the remaining 20 percent of patients is largely unknown. We tested leukemia cells from 173 children for sensitivity in vitro to prednisolone, vincristine, asparaginase, and daunorubicin. The cells were then subjected to an assessment of gene expression with the use of 14,500 probe sets to identify differentially expressed genes in drug-sensitive and drug-resistant ALL. Gene-expression patterns that differed according to sensitivity or resistance to the four drugs were compared with treatment outcome in the original 173 patients and an independent cohort of 98 children treated with the same drugs at another institution. We identified sets of differentially expressed genes in B-lineage ALL that were sensitive or resistant to prednisolone (33 genes), vincristine (40 genes), asparaginase (35 genes), or daunorubicin (20 genes). A combined gene-expression score of resistance to the four drugs, as compared with sensitivity to the four, was significantly and independently related to treatment outcome in a multivariate analysis (hazard ratio for relapse, 3.0; P=0.027). Results were confirmed in an independent population of patients treated with the same medications (hazard ratio for relapse, 11.85; P=0.019). Of the 124 genes identified, 121 have not previously been associated with resistance to the four drugs we tested. Differential expression of a relatively small number of genes is associated with drug resistance and treatment outcome in childhood ALL.

1 October 2006 in Cancer Cell
Verified
Journal Article
Closed access
GWGuo Wei
Guo Wei
DTDavid Twomey
David Twomey
JLJustin Lamb
Justin Lamb
KSKrysta Schlis
Krysta Schlis
JAJyoti Agarwal
Jyoti Agarwal
SAScott A. Armstrong
Scott A. Armstrong

1 February 2003 in Cancer Cell
Verified
Journal Article
Closed access
SAScott A Armstrong
Scott A Armstrong
AKAndrew L Kung
Andrew L Kung
MMMeghann E Mabon
Meghann E Mabon
LSLewis B Silverman
Lewis B Silverman
RSRonald W Stam
Ronald W Stam
SKStanley J Korsmeyer
Stanley J Korsmeyer

10 October 2013 in Blood
Verified
Journal Article
Open access
PDF file
AVArian van der Veer
Arian van der Veer
EWEsmé Waanders
Esmé Waanders
RPRob Pieters
Rob Pieters
MWMarieke E. Willemse
Marieke E. Willemse
SRSimon V. Van Reijmersdal
Simon V. Van Reijmersdal
MBMonique L. Den Boer
Monique L. Den Boer
Key Points: BCR-ABL1-like signature and IKZF1 deletions are clinically important to identify high-risk acute lymphoblastic patients.